Barclays’s Juno Therapeutics, Inc. JUNO Stock Holding History

Barclays’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-20,300	Closed	-$928K	–	7593
2017 Q4	$928K	Buy	20,300 +9,600	+90%	+$479K	﹤0.01%	3190
2017 Q3	$480K	Sell	10,700 -3,200	-23%	-$109K	﹤0.01%	3670
2017 Q2	$415K	Buy	13,900 +7,900	+132%	+$195K	﹤0.01%	3701
2017 Q1	$133K	Sell	6,000 -500	-8%	-$10.7K	﹤0.01%	4673
2016 Q4	$123K	Sell	6,500 -182,600	-97%	-$4.47M	﹤0.01%	4598
2016 Q3	$5.67M	Buy	+189,100	New	+$5.88M	0.01%	1197
2016 Q2	–	Sell	-164,000	Closed	-$6.23M	–	6854
2016 Q1	$6.23M	Buy	+164,000	New	+$5.71M	0.01%	1025

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Barclays's JUNO Position: Q1 2018 in Review

Barclays sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 124,704 shares — an estimated $5.7M sold.

Barclays first reported a position in JUNO in Q1 2015 and held it in 12 quarters. The position peaked at $10.6M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Barclays reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Barclays sold 124,704 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $5.7M.
Barclays first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
Barclays's Juno Therapeutics, Inc. position peaked at $10.6M in Q3 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Barclays's 13F filing for Q1 2018, filed 15 May 2018.